Contact Us
Drug Search Results
More Filters [+]

Docetaxel

Alternative Names: docetaxel, taxotere, docetaxol, anx-514, xrp6976, bind-014, bind014, bind 014, crlx-301, crlx 301, crlx301, modradoc-001, modradoc001, modradoc 001, modradoc-003, modradoc003, modradoc 003, modradoc-004, modradoc004, modradoc 004, modradoc-006, modradoc006, modradoc 006, docefrez
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Docetaxel injection is used to treat advanced or metastatic (cancer that has spread) breast cancer in patients who have previously received other cancer medicines that did not work well. It is also used together with other medicines (eg, cyclophosphamide, doxorubicin) to treat node-positive breast cancer that can be removed by surgery. Docetaxel belongs to the group of medicines called antineoplastics (cancer medicines). It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal cells may also be affected by docetaxel, other unwanted effects will also occur. (Sourced from: https://www.mayoclinic.org/drugs-supplements/docetaxel-intravenous-route/side-effects/drg-20068305?p=1)

Mechanisms of Action: Mitosis Inhibitor,Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Adenocarcinoma | Breast Cancer | Esophageal Cancer | Gastrointestinal Cancer | Head and Neck Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Prostate Cancer | Small Cell Carcinoma | Small Cell Lung Cancer | Squamous Cell Carcinoma | Oncology Unspecified | Breast Cancer | Lung Cancer | Non-Small-Cell Lung Cancer | Prostate Cancer | Small Cell Lung Cancer | Oncology Unspecified

Known Adverse Events: Dysgeusia | Pain Unspecified | Alopecia | Mucositis | Anemia | Thrombocytopenia | Neutropenia | Cross Infection | Myalgia | Dyspnea | Anorexia | Asthenia | Constipation | Diarrhea | Febrile Neutropenia

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Docetaxel

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 82

Highest Development Phases

Phase 3: Adenocarcinoma|Breast Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Prostate Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer

Phase 2: Anus Cancer|Bladder Cancer|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Melanoma|Muscle Cancer|Neuroendocrine Carcinoma|Oncology Solid Tumor Unspecified|Ovarian Cancer|Renal Cell Carcinoma|Sarcoma|Small Cell Lung Cancer|Transitional Cell Carcinoma|Uterine Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TRIPLE-SWITCH

P3

Not yet recruiting

Prostate Cancer|Adenocarcinoma

2031-03-14

CAPItello-280

P3

Active, not recruiting

Prostate Cancer

2028-07-25

NCT05616624

P2

Recruiting

Non-Small-Cell Lung Cancer

2027-12-31

CP-MGD019-02

P2

Unknown Status

Prostate Cancer

2027-09-01

Recent News Events

Date

Type

Title

12/09/2024

News Article

 Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

12/09/2024

News Article

 Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

12/09/2024

News Article

 Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

12/09/2024

News Article

 Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions